These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

792 related items for PubMed ID: 18634157

  • 1. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
    [Abstract] [Full Text] [Related]

  • 2. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE.
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [Abstract] [Full Text] [Related]

  • 3. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Figueredo MA, Rodriguez A, Ruiz-Yagüe M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R.
    J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
    [Abstract] [Full Text] [Related]

  • 4. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome.
    Salazar-Páramo M, Jara LJ, Ramos A, Barile L, Machado G, García-De La Torre I.
    Rheumatol Int; 2002 Aug; 22(4):142-7. PubMed ID: 12172952
    [Abstract] [Full Text] [Related]

  • 6. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
    Horák P, Hermanová Z, Faltýnek L, Pospísil Z, Scudla V.
    Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
    [Abstract] [Full Text] [Related]

  • 7. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC, Wong RW, Lau CS.
    Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
    [Abstract] [Full Text] [Related]

  • 8. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
    Arthritis Rheum; 2009 Apr 15; 61(4):482-7. PubMed ID: 19333973
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May 15; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 10. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies.
    Descloux E, Durieu I, Cochat P, Vital Durand D, Ninet J, Fabien N, Cimaz R.
    Rheumatology (Oxford); 2008 Feb 15; 47(2):183-7. PubMed ID: 18160418
    [Abstract] [Full Text] [Related]

  • 11. Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis.
    Meyer MF, Schnabel A, Schatz H, Gross WL.
    Semin Arthritis Rheum; 2001 Aug 15; 31(1):4-11. PubMed ID: 11503134
    [Abstract] [Full Text] [Related]

  • 12. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.
    Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE.
    Arthritis Rheum; 2006 Dec 15; 54(12):3918-25. PubMed ID: 17133599
    [Abstract] [Full Text] [Related]

  • 13. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A, de Azevedo MN, de Souza Papi JA, Petri M.
    J Rheumatol; 2009 Jun 15; 36(6):1195-9. PubMed ID: 19447935
    [Abstract] [Full Text] [Related]

  • 14. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug 15; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 15. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
    Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G.
    J Rheumatol; 2002 Mar 15; 29(3):482-6. PubMed ID: 11908560
    [Abstract] [Full Text] [Related]

  • 16. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    McLaurin EY, Holliday SL, Williams P, Brey RL.
    Neurology; 2005 Jan 25; 64(2):297-303. PubMed ID: 15668428
    [Abstract] [Full Text] [Related]

  • 17. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies.
    Naarendorp M, Spiera H.
    J Rheumatol; 1998 Mar 25; 25(3):589-92. PubMed ID: 9517786
    [Abstract] [Full Text] [Related]

  • 18. Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus.
    Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcón-Segovia D.
    J Rheumatol; 1993 Mar 25; 20(3):437-42. PubMed ID: 8478848
    [Abstract] [Full Text] [Related]

  • 19. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr 25; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM.
    Arthritis Rheum; 2009 Jan 15; 61(1):29-36. PubMed ID: 19116963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.